AMPD1 and rheumatoid arthritis: In combination the baseline DAS28-CRP, CD4+CD25 High T-cell CD39 expression and CD4+T cell expression of AMPD1 and ADORA2b contribute to a composite predictive ‘signature’, outperforming the clinical variable alone in identifying patients with early RA who subsequently achieve remission with MTX.